FDA labeling system for drugs in pregnancy

Annals of Pharmacotherapy

Volumn 35, Issue 11, 2001, Pages 1485-1489

  Boothby, L A ^a   Doering, P L ^a  

^a Piedmont Columbus Regional Midtown Medical Center   (United States)

Author keywords

Drug safety; Labeling; Pregnancy

Indexed keywords

DIGOXIN; DRUG; LEURAL; LIDOCAINE; PROPRANOLOL; SEX HORMONE BINDING GLOBULIN; UNCLASSIFIED DRUG;

DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; LACTATION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW;

EID: 0034756895     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A034     Document Type: Review

References (21)

1. Pregnancy labeling
2. Drug use during pregnancy
3. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing - FDA. Notice of public hearing; request for comments
4. Physicians' sources of information about teratogenic effects of drugs
5. Drugs during pregnancy: An issue of risk classification and information to prescribers
6. In vivo assessment of the teratogenic potential of drugs in humans
7. Pharmacokinetic changes during pregnancy and their clinical relevance
8. The effect of pregnancy on drug pharmacokinetics
9. Pharmacokinetics during pregnancy: Evidence-based maternal dose formulation
10. American Academy of Pediatrics: The transfer of drugs and other chemicals into human milk
11. Drugs in pregnancy
12. Drug excretion into breast milk
13. Clinical pharmacology and therapeutic drug monitoring in neonates and children
14. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment
15. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: A case control study
16. Teratogenic effects of antiepileptic drugs: Use of an international database on malformation and drug exposure (MADRE)